Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Summary of Significant Segment Expenses

Significant segment expenses are presented below.


		Three Months Ended June 30,								Six Months Ended June 30,
		2026				2025				2026				2025
		(in thousands)								(in thousands)
Clinical, Preclinical, and R&D Operations (1)		$	(18,314	)		$	(16,811	)		$	(37,680	)		$	(33,197	)
Chemistry, Manufacturing, and Controls (1)			(12,435	)			(6,071	)			(21,030	)			(13,028	)
General and Administrative (1)			(17,320	)			(5,731	)			(24,226	)			(11,423	)
Other Segment Items (2)			2,432				1,594				3,614				3,146
Net loss		$	(45,637	)		$	(27,019	)		$	(79,322	)		$	(54,502	)

(1) Includes depreciation expense directly allocated to respective activities.

(2) Other segment items primarily include interest and accretion income, realized gains and losses, and income taxes.